U.S. Roadside Drug Testing Market Summary

The U.S. roadside drug testing market size was valued at USD 1.17 billion in 2023 and is projected to grow at a CAGR of 4.71% from 2024 to 2030. The market outlook appears promising due to rising awareness of the risks associated with drug-impaired driving and the growing prevalence of drug use, particularly with the legalization of marijuana across many states. Law enforcement agencies are increasingly investing in advanced technologies designed to provide accurate and efficient testing, thereby ensuring public safety. In addition, strong government regulations and awareness campaigns against impaired driving are fueling the adoption of reliable roadside testing solutions. The expansion of this market is further supported by rapid technological innovations that enable faster and more effective detection of a broad range of substances.

The increase in fatalities and accidents linked to alcohol and substance abuse among drivers has emerged as a serious public health and safety concern in the U.S. This alarming trend has significantly heightened the demand for roadside drug testing, as law enforcement agencies and policymakers intensify efforts to reduce impaired driving and improve road safety. The prevalence of substance abuse has directly contributed to the rise in drug-impaired driving incidents. According to the National Highway Traffic Safety Administration (NHTSA), alcohol-impaired drivers continue to account for nearly 30% of all traffic-related fatalities, a figure that has remained consistently high over the years. Moreover, the widespread use of prescription medications, recreational marijuana, and illicit drugs has amplified the problem, resulting in a worrisome surge in drug-related crashes and deaths. These developments highlight the urgent need for comprehensive and effective roadside testing measures.

Key Market Trends & Insights

• The alcohol segment accounted for the largest share of 31.96% in 2023. Alcohol testing remains dominant as alcohol impairment is a well-documented public safety issue with established legal thresholds. Standardized testing devices such as breathalyzers are widely deployed, making alcohol testing highly accessible and reliable for law enforcement.
• The breath testing segment held the largest share of 44.44% in 2023. Breath tests are preferred for roadside screening because they are practical, non-invasive, and deliver immediate results. Law enforcement officers rely on them during traffic stops to quickly assess driver impairment while minimizing delays and ensuring efficient operations.
• The highway police segment commanded the largest market share of 90.87% in 2023. Their dominance is attributed to their primary responsibility for monitoring highways, enforcing traffic safety laws, and responding to impaired driving incidents. As first responders in traffic enforcement, highway police remain the leading users of roadside drug testing technologies.
• California led the U.S. roadside drug testing market with a revenue share of 14.50% in 2023. Its dominance is supported by a large population, extensive roadway infrastructure, and progressive drug regulation policies. These factors have contributed to California’s proactive approach in implementing advanced roadside testing technologies.
• New York is projected to experience strong growth in the coming years. The state has established itself as a leader in the development and refinement of roadside drug testing policies. Its proactive stance toward addressing drug-impaired driving has accelerated the adoption of new testing technologies, setting an example for other regions in the U.S.

Order a free sample PDF of the U.S. Roadside Drug Testing Market Intelligence Study, published by Grand View Research.

Market Size & Forecast

• 2023 Market Size: USD 1.17 billion
• 2030 Projected Market Size: USD 1.62 billion
• CAGR (2024 - 2030): 4.71%

Key Companies & Market Share Insights

Some of the leading players operating in the market include Drägerwerk AG & Co. KGaA, Abbott, Intoximeters, Lifeloc Technologies, Inc., Hound Labs, Inc., Immunalysis Corporation, CMI Inc., Alcohol Countermeasure Systems Corp., AK GlobalTech Corp., PAS Systems International, Inc. Operating strategies include developing portable, accurate testing devices and providing extensive training for law enforcement. Key market players such as Dräger, and Abbott focus on advanced technology integration and strategic partnerships with law enforcement agencies. For example, Dräger's DrugTest 5000 and Abbott's SoToxa are widely used to ensure reliable and efficient roadside drug screening, enhancing road safety and reducing impaired driving incidents.

Key Players

• Drägerwerk AG & Co. KGaA
• Abbott.
• Intoximeters
• Lifeloc Technologies, Inc.
• Hound Labs, Inc.
• Immunalysis Corporation
• CMI Inc.
• Alcohol Countermeasure Systems Corp.
• AK GlobalTech Corp.
• PAS Systems International, Inc

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion

The U.S. roadside drug testing market is witnessing steady growth, supported by increasing concerns over impaired driving, government initiatives, and the adoption of advanced testing technologies. Segments such as alcohol and breath testing continue to dominate due to established practices and reliability, while highway police remain the primary enforcers. California’s strong market share and New York’s proactive policy development reflect regional leadership in driving market advancements. With substance abuse and impaired driving incidents posing ongoing challenges, the need for effective roadside testing solutions will intensify, positioning the market as an essential component of future road safety strategies across the country.